Despite decades of reliance on animal models, poor clinical translation remains a major challenge in drug development. In oncology alone, more than 90% of candidates that demonstrate efficacy in animals ultimately fail in human trials1. To help close this gap, regulatory agencies and the pharmaceutical industry are increasingly promoting New Approach Methodologies (NAMs) to improve human relevance while reducing animal use2.
